Targeting Myeloid Leukemia Stem Cells

See allHide authors and affiliations

Science Translational Medicine  12 May 2010:
Vol. 2, Issue 31, pp. 31ps21
DOI: 10.1126/scitranslmed.3000914

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Recently, several research groups have described cell surface molecules that are selectively or differentially expressed on leukemia stem cells (LSCs) relative to normal tissue. The identification of these antigens suggests that antibody-based diagnostic or therapeutic opportunities may be forthcoming. Indeed, preclinical studies have suggested the utility of targeting such molecules as a means of enhancing leukemia therapy. Here the current understanding of the LSC phenotype is described, and the potential application of antibody-based treatment regimens is discussed.


  • Citation: C. T. Jordan, Targeting myeloid leukemia stem cells. Sci. Transl. Med. 2, 31ps21 (2010).

View Full Text

Stay Connected to Science Translational Medicine